Long-term Viltepso Prevents Motor Function Decline in DMD Boys

Long-term Viltepso Prevents Motor Function Decline in DMD Boys

299285

Long-term Viltepso Prevents Motor Function Decline in DMD Boys

Long-term treatment with Viltepso (viltolarsen) safely and effectively prevents a decline in motor function in boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. Those are the findings of two-year data from a Phase 2 trial of Viltepso, an exon-skipping therapy being developed by NS Pharma, and its extension study. “After more than two years of treatment with VILTEPSO, patients maintained their motor function based on clinically relevant measurements while the DMD historic…

You must be logged in to read/download the full post.